EXEL Exelixis, Inc. - Common Stock
$52,86
Preço · Ago 18, 2026
Fundamentais a partir de Ago 5, 2026
Intervalo 52 Semanas
$34–$58
80% of range
Classificação do Analista
HOLD
26 analysts
Preço-Alvo
$53
+0% upside
P/E (TTM)
18.4
ROE
37.3%
Margem de Lucro Líquido
33.7%
Sobre Exelixis, Inc. - Common Stock Visão geral da empresa da Wikipedia
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Ler mais
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
History
Exelixis was founded in 1994; the scientific founders were Spyridon Artavanis–Tsakonas, at Yale at that time, and Corey Goodman and Gerry Rubin who were then at the University of California, Berkeley. George Scangos joined the company as CEO in 1996. The business plan was to use model organisms (fruit flies, nematodes, and zebrafish) and functional genomics to identify pathways and biological targets that could be exploited in the fields of agriculture and medicine. It eventually set up a subsidiary, Exelixis Plant Sciences, for the agricultural work.
By 2000, Exelixis had left the radical exploratory phase behind and became focused on drug discovery and had a chemical library of 4 million compounds. The company went public that year, after withdrawing its offering the week before; it raised $118 million in a down market.
In 2002, the company signed a broad alliance with GSK to discover new drugs in the fields of cancer, inflammatory diseases, and vascular conditions; GSK paid it $30 million in cash, bought $14 million in stock at twice the market rate, and committed to providing Exelixis with $90 million in research funding; it also offered loan financing of up to $85 million.
By 2002, the company had limited its internal efforts to cancer, and had settled its strategy on discovering and developing drugs that could inhibit targeted small sets of tyrosine kinases that are needed for cancer formation, growth, and metastasis. The sets of TKs had been identified by means of its prior functional genomics work. This approach was controversial at the time; most companies try to selectively target just one protein in their discovery efforts.
In 2006, Exelixis partnered with Daiichi Sankyo on compounds that targeted mineralocorticoid receptors; esaxerenone was part of this collaboration. In 2007, the company partnered its MEK inhibitor program with Genentech; cobimetinib (at that time XL-518) was part of this collaboration. Exelixis had filed an IND on XL-518 prior to the partnership, committed to funding and running the Phase I trial, and retained rights to co-market it in the US.
In 2008, the company partnered its lead cancer drug candidate, XL-184 (which would become called cabozantinib) and another cancer candidate, XL-281, with Bristol Myers Squibb; BMS returned the rights to XL-184 to Exelixis in 2010 and returned the rights to other drug candidate in 2011.
In 2010, Scangos departed as CEO to take over at Biogen and the company appointed Michael M. Morrissey as president and CEO; Morrissey had joined the company in 2000 as Vice President of Discovery Research. At that time the company had eight drugs in clinical trials.
Exelixis' first drug approval came in 2012, when cabozantinib was approved for medullary thyroid cancer, an orphan indication. It was approved in Europe in 2014.
Exelixis invested heavily in exploring cabozantinib in other cancers, betting the future of the company on the drug. In 2014 the drug failed a Phase III trial in prostate cancer, and the company laid off 70% of its employees.
In 2015, Genentech and Exelixis won FDA approval for cobimetinib for certain forms of melanoma.
In March 2016, Exelixis licensed to Ipsen worldwide rights (outside the US, Canada, and Japan) to market cabozantinib.
In April 2016, the FDA granted approval for marketing the tablet formulation as a second line treatment for kidney cancer and the same was approved in Europe in October of that year.
In December 2017, the FDA granted approval for the use of cabozantinib for first line treatment of kidney cancer and in 2018 approval for first-line treatment was approved in Europe.
Finance
Pricing
Cabometyx (cabozantinib)
In 2023, the Institute for Clinical and Economic Review (ICER) identified Cabometyx (cabozantinib) as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Cabometyx's wholesale acquisition cost rose by 7.5%, leading to an additional $86 million in costs to U.S. payers.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
EXEL Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$52.86
Capitalização de Mercado
$13.41B
P/E (TTM)
18.4
EPS (TTM)
$2.78
Receita (TTM)
$2.32B
Rendimento div.
—
ROE
37.3%
Dívida/Capital
—
Intervalo 52 Semanas
$34 – $58
EXEL Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$2.32B
2016-12-31
→
2026-01-02
EPS
$2.78
2017-12-29
→
2026-01-02
Fluxo de caixa livre
$876M
2017-12-29
→
2026-01-02
Margens
33.7%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
EXEL
Mediana de Pares
P/E (TTM)
18.4
28.5
P/S (TTM)
5.8
20.1
P/B
6.2
12.9
Price / FCF (Preço / FCF)
15.3
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
EXEL
Mediana de Pares
Operating Margin (Margem Operacional)
37.6%
—
Net Profit Margin (Margem de Lucro Líquido)
33.7%
-48.4%
ROA
27.0%
-28.4%
ROE
37.3%
-49.2%
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
EXEL
Mediana de Pares
Current Ratio (Índice de liquidez corrente)
3.6
5.0
Quick Ratio (Índice de Liquidez Seca)
3.3
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
EXEL
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
7.0%
—
Revenue CAGR 3Y (CAGR Receita 3A)
12.9%
—
Revenue CAGR 5Y (CAGR Receita 5A)
18.6%
—
EPS YoY
58.0%
—
Net Income YoY (Lucro Líquido Ano a Ano)
50.1%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
EXEL
Mediana de Pares
EXEL Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
26 analistas
- Compra forte 5 19,2%
- Compra 8 30,8%
- Manter 12 46,2%
- Venda 1 3,8%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
16 analistas · 2026-08-13
Mediana
$52.00
Agora
$52.86
Mín
$41.00
Máx
$66.00
Alvo mediano
$52.00
-1,6%
Alvo médio
$52.94
+0,1%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.08%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $0.82 | $0.80 | 0.02% |
| 31 de Março de 2026 | $0.79 | $0.72 | 0.07% |
| 31 de Dezembro de 2025 | $0.88 | $0.82 | 0.06% |
| 30 de Setembro de 2025 | $0.69 | $0.63 | 0.06% |
| 30 de Junho de 2025 | $0.65 | $0.57 | 0.08% |
| 31 de Março de 2025 | $0.55 | $0.37 | 0.18% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 16
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $988M | $968M | $854M | $452M | $191M | $37M | |
| Cost of Revenue | $84M | $76M | $73M | $58M | $53M | $36M | $33M | $26M | $15M | $7M | $4M | |
| R&D Expense | $825M | $910M | $1.04B | $892M | $694M | $548M | $337M | $182M | $112M | $96M | $96M | |
| SG&A Expense | $519M | $492M | $543M | $460M | $402M | $293M | $228M | $206M | $159M | $116M | $57M | |
| Operating Expenses | $1.45B | $1.56B | $1.66B | $1.41B | $1.15B | $877M | $598M | $415M | $287M | $220M | $159M | |
| Operating Income | $872M | $605M | $171M | $201M | $287M | $110M | $369M | $439M | $166M | $-28M | $-121M | |
| Interest Expense | · | · | · | · | · | · | $0 | $0 | $9M | $33M | $41M | |
| Other Non-op | $-198.0K | $-133.0K | $93.0K | $-197.0K | $-184.0K | $912.0K | $680.0K | $397.0K | $-4M | $5M | $-381.0K | |
| Pretax Income | · | · | · | · | · | $131M | $398M | $452M | $159M | $-70M | $-162M | |
| Income Tax | $159M | $160M | $50M | $52M | $63M | $19M | $77M | $-238M | $4M | $0 | $55.0K | |
| Net Income | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | $-70M | $-162M | |
| EPS (Basic) | $2.88 | $1.80 | $0.65 | $0.57 | $0.73 | $0.36 | $1.06 | $2.32 | $0.52 | · | $-0.77 | |
| EPS (Diluted) | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 | $0.35 | $1.02 | $2.21 | $0.49 | · | $-0.77 | |
| Shares (Basic) | 271,567,000 | 290,030,000 | 318,151,000 | 321,526,000 | 314,884,000 | 308,271,000 | 302,584,000 | 297,892,000 | 293,588,000 | · | 209,227,000 | |
| Shares (Diluted) | 281,863,000 | 296,132,000 | 321,464,000 | 324,556,000 | 322,359,000 | 318,001,000 | 315,009,000 | 312,803,000 | 312,003,000 | · | 209,227,000 | |
| EBITDA | $901M | $633M | $197M | $222M | $300M | $119M | $378M | $444M | $167M | · | · |
Balanço Patrimonial 27
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $482M | $217M | $263M | $501M | $647M | $319M | $267M | $315M | $183M | $152M | $142M | |
| Short-term Investments | $577M | $894M | $732M | $807M | $820M | $887M | $586M | $379M | $205M | $268M | · | |
| Receivables | $287M | $265M | $237M | $215M | $283M | $161M | $119M | $163M | $77M | $40M | · | |
| Inventory | $22M | $22M | $17M | $33M | $27M | $21M | $13M | $10M | $7M | $3M | · | |
| Prepaid Expense | $76M | $68M | $68M | $62M | $58M | $57M | $27M | $31M | $9M | $5M | · | |
| Current Assets | $1.44B | $1.47B | $1.32B | $1.62B | $1.83B | $1.45B | $1.01B | $897M | $485M | $469M | · | |
| PP&E (Net) | $99M | $119M | $129M | $111M | $104M | $67M | $49M | $51M | $26M | $2M | · | |
| PP&E (Gross) | $231M | $220M | $209M | $171M | $145M | $102M | $74M | $68M | $49M | $27M | · | |
| Accum. Depreciation | $132M | $101M | $80M | $61M | $41M | $35M | $26M | $17M | $23M | $25M | · | |
| Goodwill | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | · | |
| Other Non-current Assets | · | · | · | · | $131M | $73M | $53M | $8M | $12M | $1M | · | |
| Total Assets | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655M | $596M | · | |
| Accounts Payable | $30M | $38M | $34M | $33M | $24M | $24M | $12M | $11M | $10M | $7M | · | |
| Short-term Debt | · | · | · | · | · | · | · | · | $0 | $80M | · | |
| Current Liabilities | $406M | $404M | $394M | $324M | $338M | $205M | $143M | $105M | $115M | $269M | · | |
| Capital Leases | $173M | $191M | $190M | $190M | $51M | $49M | $48M | $12M | $15M | · | · | |
| Other Non-current Liabilities | $104M | $109M | $94M | $69M | $8M | $721.0K | $2M | $1M | $2M | $541.0K | · | |
| Total Liabilities | $683M | $703M | $678M | $583M | $406M | $258M | $200M | $135M | $370M | $506M | · | |
| Long-term Debt | · | · | · | · | · | · | · | · | $0 | $189M | · | |
| Total Debt | · | · | · | · | · | · | · | · | $0 | · | · | |
| Common Stock | $262.0K | $282.0K | $303.0K | $324.0K | $319.0K | $312.0K | $305.0K | $300.0K | $296.0K | $290.0K | · | |
| Paid-in Capital | $2.23B | $2.34B | $2.44B | $2.54B | $2.43B | $2.32B | $2.24B | $2.17B | $2.11B | $2.07B | · | |
| Retained Earnings | $-77M | $-99M | $-173M | $-34M | $-217M | $-448M | $-559M | $-880M | $-1.83B | $-1.98B | · | |
| AOCI | $3M | $-1M | $-4M | $-15M | $-758.0K | $4M | $3M | $-701.0K | $-347.0K | $-416.0K | · | |
| Stockholders' Equity | $2.16B | $2.24B | $2.26B | $2.49B | $2.21B | $1.88B | $1.69B | $1.29B | $285M | $89M | $-141M | |
| Liabilities + Equity | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655M | $596M | · | |
| Shares Outstanding | 262,483,000 | 281,732,000 | 302,793,000 | 323,951,000 | 318,842,000 | 311,627,000 | 304,831,000 | 299,876,000 | 296,209,000 | 289,923,798 | 227,960,943 |
Fluxo de Caixa 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $29M | $29M | $26M | $21M | $14M | $9M | $8M | $5M | $1M | $1M | $1M | |
| Stock-based Comp | $113M | $94M | $106M | $108M | $120M | $105M | $57M | $41M | $24M | $23M | $22M | |
| Deferred Tax | $126M | $-59M | $-133M | $-60M | $47M | $15M | $71M | $-244M | $0 | $0 | $0 | |
| Restructuring | $21M | $34M | $0 | $0 | · | · | · | $0 | $-32.0K | $63M | $1M | |
| Other Non-cash | $-167M | $116M | $127M | $112M | $-10M | $-32M | $70M | $-76M | $-14M | · | · | |
| Operating Cash Flow | $884M | $700M | $333M | $363M | $401M | $209M | $527M | $416M | $166M | $206M | $-141M | |
| CapEx | $8M | $28M | $40M | $28M | $54M | $30M | $13M | $33M | $21M | $2M | $447.0K | |
| Investing Cash Flow | $350M | $-117M | $-27M | $-524M | $-43M | $-131M | $-587M | $-298M | $37M | $-216M | $50M | |
| Net Debt Issued | · | · | · | · | · | · | $0 | $0 | $-186M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $0 | $0 | $146M | |
| Stock Repurchased | $948M | $652M | $550M | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | $-948M | $-652M | $-550M | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $-970M | $-629M | $-546M | $586.0K | $-15M | $-25M | $13M | $10M | $-170M | $20M | $152M | |
| Net Change in Cash | $265M | $-46M | $-240M | $-161M | $343M | $53M | $-48M | $128M | $32M | $10M | $61M | |
| Taxes Paid | $155M | $170M | $186M | $128M | $13M | $4M | $8M | $11M | $538.0K | · | · | |
| Free Cash Flow | $876M | $672M | $293M | $335M | $337M | $179M | $514M | $382M | $144M | · | · | |
| Levered FCF | · | · | · | · | · | · | $514M | $382M | $136M | · | · |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | 11.1% | 38.2% | 51.4% | 36.7% | · | · | |
| Net Margin | 33.7% | 24.0% | 11.3% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | · | · | |
| Pretax Margin | · | · | · | · | · | 13.2% | 41.1% | 52.9% | 35.0% | · | · | |
| EBITDA Margin | 38.8% | 29.2% | 10.7% | 13.8% | 20.9% | 12.1% | 39.0% | 52.0% | 36.9% | · | · | |
| ROA | 27.0% | 17.7% | 6.9% | 6.4% | 9.7% | 5.6% | 19.4% | 66.4% | 24.7% | · | · | |
| ROE | 37.3% | 23.1% | 9.0% | 7.3% | 10.7% | 6.0% | 19.5% | 62.6% | 82.4% | · | · | |
| ROIC | · | · | · | · | · | 5.0% | 17.7% | 52.0% | 56.6% | · | · |
Liquidez e Solvência 4
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | 3.6 | 3.3 | 5.0 | 5.4 | 7.1 | 7.1 | 8.5 | 4.2 | · | · | |
| Quick Ratio | 3.3 | 3.4 | 3.1 | 4.7 | 5.2 | 6.7 | 6.8 | 8.1 | 4.1 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 0.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 19.1 | · | · |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.7 | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 | 0.8 | 0.7 | · | · | |
| Inventory Turnover | 3.8 | 3.8 | 2.9 | 1.9 | 2.2 | 2.1 | 2.9 | 3.2 | 3.0 | · | · | |
| Receivables Turnover | 8.4 | 8.6 | 8.1 | 6.5 | 6.5 | 7.1 | 6.9 | 9.8 | 7.4 | · | · |
Taxas de Crescimento 9
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.0% | 18.5% | 13.6% | 12.3% | 45.3% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.9% | 14.8% | 22.8% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 18.6% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 58.0% | 170.8% | 16.1% | -22.2% | 105.7% | · | · | · | · | · | · | |
| EPS CAGR 3Y | 70.6% | 34.7% | 22.9% | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 51.3% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 50.1% | 150.9% | 14.0% | -21.1% | 106.7% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 62.5% | 31.1% | 22.9% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 47.6% | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 14
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $988M | $968M | $854M | $452M | · | $37M | |
| Net Income TTM | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | · | $-162M | |
| Market Cap | $11.44B | $9.57B | $7.26B | $5.20B | $5.83B | $6.25B | $5.19B | $5.83B | $9.00B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $8.62B | · | · | |
| P/E | 15.7 | 19.3 | 36.9 | 28.6 | 25.4 | 57.3 | 16.7 | 8.8 | 62.0 | · | -7.3 | |
| P/S | 4.9 | 4.4 | 4.0 | 3.2 | 4.1 | 6.3 | 5.4 | 6.8 | 19.9 | · | · | |
| P/B | 5.3 | 4.3 | 3.2 | 2.1 | 2.6 | 3.3 | 3.1 | 4.5 | 31.6 | · | · | |
| P / Tangible Book | 5.5 | 4.4 | 3.3 | 2.1 | 2.7 | 3.4 | · | · | · | · | · | |
| P / Cash Flow | 12.9 | 13.7 | 21.8 | 14.3 | 14.5 | 29.9 | 9.8 | 14.0 | 54.4 | · | · | |
| P / FCF | 13.1 | 14.3 | 24.8 | 15.5 | 17.3 | 35.0 | 10.1 | 15.2 | 62.3 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | 51.6 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | 59.6 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 19.0 | · | · | |
| Earnings Yield | 6.4% | 5.2% | 2.7% | 3.5% | 3.9% | 1.7% | 6.0% | 11.4% | 1.6% | · | -13.7% |
Demonstração de Resultados 14
| Métrica | Tendência | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $629M | $611M | $718M | $598M | $568M | $555M | $818M | $540M | $637M | $425M | $480M | $472M | $470M | $409M | $424M | $412M | |
| Cost of Revenue | $21M | $20M | $27M | $19M | $19M | $19M | $25M | $17M | $18M | $21M | $22M | $19M | $18M | $14M | $16M | $15M | |
| R&D Expense | $212M | $200M | $164M | $199M | $200M | $212M | $111M | $223M | $211M | $228M | $245M | $333M | $233M | $234M | $337M | $199M | |
| SG&A Expense | $148M | $140M | $161M | $124M | $135M | $137M | $81M | $112M | $132M | $114M | $131M | $138M | $142M | $131M | $119M | $115M | |
| Operating Expenses | $380M | $359M | $287M | $361M | $355M | $369M | $303M | $403M | $361M | $396M | $398M | $490M | $392M | $380M | $472M | $329M | |
| Operating Income | $248M | $251M | $431M | $237M | $214M | $187M | $516M | $136M | $276M | $29M | $82M | $-18M | $78M | $29M | $-48M | $83M | |
| Other Non-op | $54.0K | $219.0K | $207.0K | $-49.0K | $50.0K | $-245.0K | $-363.0K | $-29.0K | $-287.0K | $-89.0K | $-137.0K | $289.0K | $-5.0K | $-54.0K | $-337.0K | $-69.0K | |
| Income Tax | $51M | $57M | $43M | $59M | $46M | $46M | $128M | $37M | $67M | $12M | $18M | $5M | $19M | $8M | $-1M | $19M | |
| Net Income | $212M | $210M | $401M | $194M | $185M | $160M | $399M | $118M | $226M | $37M | $86M | $1M | $81M | $40M | $-30M | $73M | |
| EPS (Basic) | $0.85 | $0.81 | $1.57 | $0.72 | $0.68 | $0.57 | $1.43 | $0.41 | $0.78 | $0.12 | $0.28 | $0.00 | $0.25 | $0.12 | $-0.09 | $0.23 | |
| EPS (Diluted) | $0.82 | $0.79 | $1.49 | $0.69 | $0.65 | $0.55 | $1.39 | $0.40 | $0.77 | $0.12 | $0.28 | $0.00 | $0.25 | $0.12 | $-0.09 | $0.23 | |
| Shares (Basic) | 250,808,000 | 258,329,000 | -604,028,000 | 268,421,000 | 272,583,000 | 278,804,000 | -674,091,000 | 285,622,000 | 289,216,000 | 300,757,000 | -645,970,000 | 315,496,000 | 324,205,000 | 324,420,000 | 577,000 | 322,148,000 | |
| Shares (Diluted) | 259,675,000 | 267,322,000 | -609,119,000 | 278,535,000 | 284,393,000 | 288,177,000 | -676,699,000 | 291,478,000 | 293,974,000 | 305,530,000 | -651,367,000 | 319,247,000 | 327,305,000 | 326,279,000 | 136,000 | 325,066,000 | |
| EBITDA | $248M | $258M | · | $237M | $214M | $194M | · | $136M | $276M | $36M | · | $-18M | $78M | $36M | · | $83M |
Balanço Patrimonial 24
| Métrica | Tendência | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $281M | $226M | $482M | $376M | $164M | $184M | $217M | $258M | $198M | $260M | · | $397M | $464M | $541M | · | $675M | |
| Short-term Investments | $558M | $551M | $577M | $612M | $627M | $848M | $894M | $931M | $804M | $704M | · | $707M | $802M | $773M | · | $872M | |
| Receivables | $322M | $329M | $287M | $310M | $292M | $282M | $265M | $270M | $397M | $241M | · | $248M | $233M | $234M | · | $215M | |
| Inventory | $29M | $27M | $22M | $27M | $23M | $25M | $22M | $21M | $21M | $21M | · | $25M | $29M | $30M | · | $27M | |
| Prepaid Expense | $60M | $76M | $76M | $77M | $74M | $59M | $68M | $70M | $58M | $67M | · | $67M | $62M | $61M | · | $53M | |
| Current Assets | $1.25B | $1.21B | $1.44B | $1.40B | $1.18B | $1.40B | $1.47B | $1.55B | $1.48B | $1.29B | · | $1.44B | $1.59B | $1.64B | · | $1.84B | |
| PP&E (Net) | $93M | $96M | $99M | $105M | $110M | $115M | $119M | $124M | $130M | $127M | · | $121M | $115M | $116M | · | $108M | |
| PP&E (Gross) | · | · | $231M | · | · | · | $220M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $132M | · | · | · | $101M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | · | $64M | $64M | $64M | · | $64M | |
| Other Non-current Assets | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $280M | |
| Total Assets | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | · | $2.98B | $3.14B | $3.14B | · | $2.96B | |
| Accounts Payable | $39M | $24M | $30M | $25M | $26M | $43M | $38M | $59M | $29M | $26M | · | $26M | $26M | $33M | · | $31M | |
| Current Liabilities | $362M | $371M | $406M | $374M | $336M | $399M | $404M | $394M | $346M | $373M | · | $377M | $340M | $328M | · | $302M | |
| Capital Leases | $166M | $170M | $173M | $176M | $180M | $187M | $191M | $194M | $198M | $201M | · | $191M | $195M | $187M | · | $160M | |
| Other Non-current Liabilities | $123M | $117M | $104M | $113M | $129M | $120M | $109M | $96M | $110M | $101M | · | $62M | $73M | $67M | · | $2M | |
| Total Liabilities | $650M | $658M | $683M | $663M | $645M | $706M | $703M | $685M | $653M | $676M | · | $629M | $615M | $588M | · | $470M | |
| Common Stock | $249.0K | $254.0K | $262.0K | $268.0K | $270.0K | $275.0K | $282.0K | $286.0K | $285.0K | $295.0K | · | $311.0K | $320.0K | $325.0K | · | $323.0K | |
| Paid-in Capital | $2.11B | $2.15B | $2.23B | $2.26B | $2.25B | $2.29B | $2.34B | $2.36B | $2.32B | $2.39B | · | $2.49B | $2.53B | $2.56B | · | $2.51B | |
| Retained Earnings | $-263M | $-216M | $-77M | $-106M | $-220M | $-163M | $-99M | $-90M | $-200M | $-259M | · | $-126M | $11M | $6M | · | $-4M | |
| AOCI | $-2M | $-415.0K | $3M | $4M | $1M | $2M | $-1M | $4M | $-5M | $-5M | · | $-14M | $-14M | $-9M | · | $-18M | |
| Stockholders' Equity | $1.84B | $1.94B | $2.16B | $2.16B | $2.03B | $2.13B | $2.24B | $2.28B | $2.12B | $2.13B | $2.26B | $2.35B | $2.53B | $2.56B | $2.49B | $2.49B | |
| Liabilities + Equity | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | · | $2.98B | $3.14B | $3.14B | · | $2.96B | |
| Shares Outstanding | 248,885,000 | 253,701,000 | 262,483,000 | 268,098,000 | 270,132,000 | 275,033,000 | 281,732,000 | 285,780,000 | 285,222,000 | 295,032,000 | 302,793,000 | 310,970,000 | 320,253,000 | 324,985,000 | 323,951,000 | 322,541,000 |
Fluxo de Caixa 12
| Métrica | Tendência | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $8M | $7M | $7M | $7M | $10M | $7M | $7M | $6M | $7M | $6M | $6M | $7M | $6M | $6M | |
| Stock-based Comp | $33M | $29M | $45M | $31M | $36M | $26M | $12M | $23M | $25M | $19M | $24M | $40M | $25M | $17M | $26M | $37M | |
| Restructuring | · | · | $-13M | $20M | $0 | $0 | $34M | $96.0K | $475.0K | $33M | · | $0 | $0 | $0 | · | · | |
| Other Non-cash | · | $5M | · | · | · | $19M | · | · | · | $6M | · | · | · | $21M | · | · | |
| Operating Cash Flow | $308M | $252M | $425M | $290M | $49M | $211M | $377M | $271M | $120M | $69M | $11M | $117M | $121M | $84M | $74M | $110M | |
| CapEx | $7M | $2M | $-16M | $1M | $3M | $3M | $1M | $8M | $7M | $10M | $13M | $9M | $6M | $12M | $10M | $43.0K | |
| Investing Cash Flow | $91M | $-51M | $374M | $25M | $248M | $50M | $-28M | $-217M | $82M | $112M | $62M | $35M | $-74M | $-50M | $-246M | $-69M | |
| Stock Repurchased | $323M | $430M | $486M | $104M | $302M | $284M | $311M | $12M | $264M | $185M | $209M | $217M | $124M | $0 | $0 | $0 | |
| Net Stock Activity | · | $-430M | · | · | · | $-284M | · | · | · | $-185M | · | · | · | · | · | · | |
| Financing Cash Flow | $-344M | $-457M | $-529M | $-104M | $-316M | $-295M | $-289M | $6M | $-262M | $-184M | $-206M | $-220M | $-125M | $5M | $-2M | $-2M | |
| Net Change in Cash | $55M | $-256M | $270M | $212M | $-19M | $-34M | $60M | $60M | $-61M | $-3M | $-134M | $-68M | $-78M | $39M | $-174M | $39M | |
| Free Cash Flow | · | $250M | · | · | · | $208M | · | · | · | $59M | · | · | · | $72M | · | · |
Lucratividade 5
| Métrica | Tendência | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.5% | 41.1% | · | 39.6% | 37.6% | 33.6% | · | 25.2% | 43.3% | 6.9% | · | -3.7% | 16.6% | 7.0% | · | 20.1% | |
| Net Margin | 33.7% | 34.5% | · | 32.4% | 32.5% | 28.7% | · | 21.9% | 35.5% | 8.8% | · | 0.22% | 17.3% | 9.8% | · | 17.8% | |
| EBITDA Margin | 39.5% | 42.3% | · | 39.6% | 37.6% | 35.0% | · | 25.2% | 43.3% | 8.4% | · | -3.7% | 16.6% | 8.7% | · | 20.1% | |
| ROA | 8.2% | 7.8% | · | 6.7% | 6.8% | 5.7% | · | 4.0% | 7.6% | 1.2% | · | 0.04% | 2.7% | 1.4% | · | 2.7% | |
| ROE | 10.9% | 10.3% | · | 8.7% | 8.9% | 7.5% | · | 5.1% | 9.7% | 1.6% | · | 0.04% | 3.3% | 1.7% | · | 3.2% |
Liquidez e Solvência 2
| Métrica | Tendência | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.3 | · | 3.8 | 3.5 | 3.5 | · | 3.9 | 4.3 | 3.5 | · | 3.8 | 4.7 | 5.0 | · | 6.1 | |
| Quick Ratio | 3.2 | 3.0 | · | 3.5 | 3.2 | 3.3 | · | 3.7 | 4.0 | 3.2 | · | 3.6 | 4.4 | 4.7 | · | 5.8 |
Eficiência 3
| Métrica | Tendência | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.8 | · | 0.8 | 0.7 | 0.8 | · | 0.7 | 0.6 | 0.5 | · | 0.6 | |
| Receivables Turnover | 2.0 | 2.0 | · | 2.1 | 1.6 | 2.1 | · | 2.1 | 2.0 | 1.8 | · | 2.0 | 2.0 | 1.9 | · | 2.1 |
Avaliação (TTM) 10
| Métrica | Tendência | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.41B | $2.33B | · | $2.26B | $2.30B | $2.16B | · | $2.07B | $2.00B | $1.78B | · | $1.76B | $1.71B | $1.60B | · | $1.52B | |
| Net Income TTM | $801M | $749M | · | $656M | $689M | $541M | · | $382M | $346M | $160M | · | $195M | $265M | $252M | · | $251M | |
| Market Cap | $13.90B | $11.13B | · | $10.75B | $12.47B | $9.51B | · | $7.42B | $6.41B | $7.00B | · | $6.79B | $6.12B | $6.31B | · | $5.06B | |
| P/E | 18.9 | 16.4 | · | 17.5 | 19.5 | 18.8 | · | 20.1 | 19.7 | 48.4 | · | 36.4 | 23.3 | 24.9 | · | 20.1 | |
| P/S | 5.8 | 4.8 | · | 4.8 | 5.4 | 4.4 | · | 3.6 | 3.2 | 3.9 | · | 3.9 | 3.6 | 4.0 | · | 3.3 | |
| P/B | 7.5 | 5.8 | · | 5.0 | 6.1 | 4.5 | · | 3.3 | 3.0 | 3.3 | · | 2.9 | 2.4 | 2.5 | · | 2.0 | |
| P / Tangible Book | 7.8 | 5.9 | · | 5.1 | 6.3 | 4.6 | · | 3.4 | 3.1 | 3.4 | · | 3.0 | 2.5 | 2.5 | · | 2.1 | |
| P / Cash Flow | · | 44.2 | · | · | · | 45.0 | · | · | · | 101.7 | · | · | · | 74.7 | · | · | |
| P / FCF | · | 44.5 | · | · | · | 45.6 | · | · | · | 118.4 | · | · | · | 87.1 | · | · | |
| Earnings Yield | 5.3% | 6.1% | · | 5.7% | 5.1% | 5.3% | · | 5.0% | 5.1% | 2.1% | · | 2.8% | 4.3% | 4.0% | · | 5.0% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B |
| Margem Operacional % | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% |
| Lucro líquido | $783M | $521M | $208M | $182M | $231M |
| EPS Diluído | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 |
Balanço Patrimonial
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 3.6 | 3.6 | 3.3 | 5.0 | 5.4 |
| Índice de Liquidez Seca | 3.3 | 3.4 | 3.1 | 4.7 | 5.2 |
Fluxo de Caixa
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $876M | $672M | $293M | $335M | $337M |
Últimas notícias Notícias recentes mencionando esta empresa
Sinais de trading Sinais recentes de compra/venda com preço de entrada e relação risco/recompensa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 811 declarantes · $9.1B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 135 (+27 vs trimestre anterior) | 61 (-13 vs trimestre anterior) | 240 (-1 vs trimestre anterior) | 274 (+16 vs trimestre anterior) | +39.8M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $732.794.424 | 13.468.010 | 8,04% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $730.617.099 | 13.427.993 | 8,01% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $655.266.268 | 12.043.122 | 7,19% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $595.843.747 | 10.950.997 | 6,53% | Ações |
| STATE STREET CORP | $542.471.563 | 9.970.071 | 5,95% | Ações |
| FULLER & THALER ASSET MANAGEMENT, INC. | $485.848.030 | 8.929.389 | 5,33% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $362.702.104 | 6.664.894 | 3,98% | Ações |
| D. E. Shaw & Co., Inc. | $281.389.313 | 5.171.647 | 3,09% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $237.550.034 | 4.365.926 | 2,60% | Ações |
| TWO SIGMA INVESTMENTS, LP | $229.058.537 | 4.209.861 | 2,51% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $221.832.835 | 4.077.060 | 2,43% | Ações |
| ASSETMARK, INC | $186.834.364 | 3.433.824 | 2,05% | Ações |
| Stephens Investment Management Group LLC | $147.451.698 | 2.710.011 | 1,62% | Ações |
| NORGES BANK | $146.301.199 | 2.688.866 | 1,60% | Ações |
| FIRST TRUST ADVISORS LP | $138.383.701 | 2.543.353 | 1,52% | Ações |
| Caisse de depot et placement du Quebec | $113.950.809 | 2.094.299 | 1,25% | Ações |
| GOLDMAN SACHS GROUP INC | $106.578.308 | 1.958.800 | 1,17% | Ações |
| AMERICAN CENTURY COMPANIES INC | $97.484.439 | 1.791.664 | 1,07% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $86.563.209 | 1.590.943 | 0,95% | Ações |
| Caligan Partners LP | $84.512.985 | 1.553.262 | 0,93% | Ações |
| MILLENNIUM MANAGEMENT LLC | $66.309.793 | 1.218.706 | 0,73% | Ações |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $63.086.055 | 1.159.457 | 0,69% | Ações |
| BANK OF AMERICA CORP /DE/ | $58.788.318 | 1.080.469 | 0,64% | Ações |
| Robeco Institutional Asset Management B.V. | $56.032.453 | 1.029.819 | 0,61% | Ações |
| ENVESTNET ASSET MANAGEMENT INC | $51.671.488 | 949.669 | 0,57% | Ações |
| FMR LLC | $48.839.667 | 897.623 | 0,54% | Ações |
| Gotham Asset Management, LLC | $48.569.794 | 892.663 | 0,53% | Ações |
| Swedbank AB | $45.801.141 | 841.778 | 0,50% | Ações |
| Allspring Global Investments Holdings, LLC | $44.544.520 | 825.510 | 0,49% | Ações |
| Retirement Systems of Alabama | $44.107.739 | 810.655 | 0,48% | Ações |
| BOOTHBAY FUND MANAGEMENT, LLC | $43.750.809 | 804.095 | 0,48% | Ações |
| RAYMOND JAMES FINANCIAL INC | $41.924.320 | 770.526 | 0,46% | Ações |
| Capital Impact Advisors, LLC | $41.061.268 | 754.664 | 0,45% | Ações |
| BlackRock, Inc. | $40.753.525 | 749.008 | 0,45% | Ações |
| RHUMBLINE ADVISERS | $35.723.294 | 656.559 | 0,39% | Ações |
| CANADA PENSION PLAN INVESTMENT BOARD | $35.464.438 | 651.800 | 0,39% | Ações |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $34.721.830 | 639.680 | 0,38% | Ações |
| MARSHALL WACE, LLP | $34.322.590 | 630.814 | 0,38% | Ações |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $34.315.027 | 630.675 | 0,38% | Ações |
| AMERIPRISE FINANCIAL INC | $32.255.716 | 592.827 | 0,35% | Ações |
| BARCLAYS PLC | $31.502.574 | 578.985 | 0,35% | Ações |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $31.496.480 | 578.873 | 0,35% | Ações |
| Arbejdsmarkedets Tillaegspension | $30.855.911 | 567.100 | 0,34% | Ações |
| Pictet Asset Management Holding SA | $30.153.926 | 555.438 | 0,33% | Ações |
| California Public Employees Retirement System | $29.366.600 | 539.728 | 0,32% | Ações |
| CAPITAL FUND MANAGEMENT S.A. | $28.686.856 | 527.235 | 0,31% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $28.655.734 | 526.663 | 0,31% | Ações |
| JANUS HENDERSON GROUP PLC | $26.675.806 | 621.814 | 0,29% | Ações |
| Woodline Partners LP | $26.411.049 | 485.408 | 0,29% | Ações |
| Driehaus Capital Management LLC | $26.025.500 | 478.322 | 0,29% | Ações |
| EULAV Asset Management | $25.901.500 | 476.043 | 0,28% | Ações |
| Squarepoint Ops LLC | $25.774.398 | 473.707 | 0,28% | Ações |
| Swiss National Bank | $25.648.874 | 471.400 | 0,28% | Ações |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $25.156.355 | 462.348 | 0,28% | Ações |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24.600.555 | 452.133 | 0,27% | Ações |
| IEQ CAPITAL, LLC | $24.580.697 | 451.768 | 0,27% | Ações |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $23.831.580 | 438.000 | 0,26% | Ações |
| Baird Financial Group, Inc. | $23.565.461 | 433.109 | 0,26% | Ações |
| FRANKLIN RESOURCES INC | $23.480.472 | 431.547 | 0,26% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23.347.331 | 429.100 | 0,26% | Opção de compra |
| Assenagon Asset Management S.A. | $23.324.098 | 428.673 | 0,26% | Ações |
| BANK OF NOVA SCOTIA | $22.837.676 | 419.730 | 0,25% | Ações |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $22.615.516 | 415.650 | 0,25% | Ações |
| South Street Advisors LLC | $22.275.019 | 409.392 | 0,24% | Ações |
| Bridgewater Associates, LP | $21.810.738 | 400.859 | 0,24% | Ações |
| VICTORY CAPITAL MANAGEMENT INC | $21.480.143 | 394.783 | 0,24% | Ações |
| ROYAL BANK OF CANADA | $20.031.000 | 368.153 | 0,22% | Ações |
| SEI INVESTMENTS CO | $19.897.640 | 365.698 | 0,22% | Ações |
| LAZARD ASSET MANAGEMENT LLC | $18.664.208 | 343.029 | 0,20% | Ações |
| Nuveen, LLC | $18.299.226 | 336.321 | 0,20% | Ações |
| Nuveen Asset Management, LLC | $18.252.629 | 548.127 | 0,20% | Ações |
| NFJ INVESTMENT GROUP, LLC | $17.880.160 | 328.619 | 0,20% | Ações |
| SAWGRASS ASSET MANAGEMENT LLC | $17.808.447 | 327.301 | 0,20% | Ações |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $17.565.616 | 322.838 | 0,19% | Ações |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $17.472.485 | 407.379 | 0,19% | Ações |
| ING GROEP NV | $16.943.274 | 311.400 | 0,19% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $16.529.758 | 303.800 | 0,18% | Opção de venda |
| Brandywine Global Investment Management, LLC | $16.490.117 | 376.229 | 0,18% | Ações |
| CAPTRUST FINANCIAL ADVISORS | $16.488.532 | 303.042 | 0,18% | Ações |
| INTECH INVESTMENT MANAGEMENT LLC | $16.262.224 | 298.883 | 0,18% | Ações |
| HighTower Advisors, LLC | $15.842.121 | 291.162 | 0,17% | Ações |
| SEIZERT CAPITAL PARTNERS, LLC | $15.411.796 | 283.253 | 0,17% | Ações |
| Trexquant Investment LP | $14.974.122 | 275.209 | 0,16% | Ações |
| Clark Capital Management Group, Inc. | $14.792.882 | 271.878 | 0,16% | Ações |
| ALLIANCEBERNSTEIN L.P. | $14.763.381 | 344.215 | 0,16% | Ações |
| VAN ECK ASSOCIATES CORP | $14.270.709 | 262.281 | 0,16% | Ações |
| GLOBEFLEX CAPITAL L P | $13.874.169 | 254.993 | 0,15% | Ações |
| Sofinnova Investments, Inc. | $13.831.022 | 254.200 | 0,15% | Opção de venda |
| JANE STREET GROUP, LLC | $13.815.570 | 253.916 | 0,15% | Ações |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $13.724.052 | 252.234 | 0,15% | Ações |
| Voleon Capital Management LP | $13.682.047 | 251.462 | 0,15% | Ações |
| BLAIR WILLIAM & CO/IL | $13.233.352 | 243.215 | 0,15% | Ações |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $13.027.000 | 239.418 | 0,14% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12.745.021 | 297.156 | 0,14% | Ações |
| MERITAGE PORTFOLIO MANAGEMENT | $12.679.099 | 289.279 | 0,14% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $12.516.694 | 230.044 | 0,14% | Ações |
| Susquehanna Portfolio Strategies, LLC | $12.500.643 | 229.749 | 0,14% | Ações |
| MILLENNIUM MANAGEMENT LLC | $12.035.492 | 221.200 | 0,13% | Opção de compra |
| Illinois Municipal Retirement Fund | $11.750.764 | 215.967 | 0,13% | Ações |
| CWM, LLC | $11.300.486 | 263.476 | 0,12% | Ações |
Executivos da empresa 43 insiders · 22 diretores · 10 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Michael Morrissey | President and CEO | 18 de Maio de 2026 G | 2.004.327 | 0 | 0 | $0 |
| Christopher J. Senner | EVP and CFO | 18 de Maio de 2026 S | 952.317 | 0 | 3 | $-4.556.048 |
| Deborah Burke | SVP & Chief Financial Officer | 15 de Novembro de 2014 M | 18.156 | 0 | 0 | $0 |
| Frank Karbe | EVP and CFO | 15 de Fevereiro de 2014 M | 93.990 | 0 | 0 | $0 |
| Kristine M Ball | Controller & Interim CFO | 10 de Dezembro de 2003 A | 4.913 | 0 | 0 | $0 |
| Patrick J. Haley | EVP, Commercial | 20 de Maio de 2026 S | 357.638 | 0 | 7 | $-7.597.268 |
| Brenda Hefti | SVP and General Counsel | 18 de Maio de 2026 S | 106.762 | 0 | 2 | $-1.154.264 |
| Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | 16 de Maio de 2025 M | 465.393 | 0 | 0 | $0 |
| Jeffrey Hessekiel | EVP & General Counsel | 15 de Maio de 2025 S | 693.396 | 0 | 0 | $0 |
| Vicki L Goodman | EVP, Prod Dev & Med Aff &CMO | 3 de Abril de 2023 A | 307.654 | 0 | 0 | $0 |
| Peter Lamb | EVP, Scientific Strategy & CSO | 15 de Dezembro de 2022 M | 410.958 | 0 | 0 | $0 |
| Gisela Schwab | Pres, Prod Dev & Med Aff & CMO | 26 de Julho de 2021 M | 689.078 | 0 | 0 | $0 |
| Pamela A Simonton | EVP and General Counsel | 15 de Novembro de 2013 M | 17.139 | 0 | 0 | $0 |
| Lupe M Rivera | EVP, Operations | 15 de Agosto de 2011 M | 19.219 | 0 | 0 | $0 |
| Frances K Heller | EVP, Business Development | 15 de Maio de 2011 M | 17.125 | 0 | 0 | $0 |
| Ian D Malcolm | VP, STRATEGIC MARKETING | 8 de Dezembro de 2006 A | — | 0 | 0 | $0 |
| Christoph Pereira | VP, Legal Affairs & Secretary | 8 de Dezembro de 2006 A | — | 0 | 0 | $0 |
| Jeffrey Latts | Executive VP, Development | 8 de Dezembro de 2006 A | — | 0 | 0 | $0 |
| Gregory Plowman | Sr VP, CSO | 13 de Dezembro de 2004 A | — | 0 | 0 | $0 |
| Steven P James | Sr VP, Commercial Ops | 10 de Dezembro de 2003 A | — | 0 | 0 | $0 |
| Jane M Green | VP, Corp Communications | 10 de Dezembro de 2003 A | — | 0 | 0 | $0 |
| Geoffrey M Duyk | Pres R&D & CSO | 4 de Novembro de 2003 S | 941.355 | 0 | 0 | $0 |
| Alan M Garber | Conselheiro | 21 de Março de 2024 M | 35.703 | 0 | 0 | $0 |
| Jacqueline Wright | Conselheiro | 1 de Junho de 2023 A | 51.756 | 0 | 0 | $0 |
| Carl B Feldbaum | Conselheiro | 9 de Fevereiro de 2023 M | 18.701 | 0 | 0 | $0 |
| Lance Willsey | Conselheiro | 26 de Maio de 2022 A | 424.415 | 0 | 0 | $0 |
| Vincent T Marchesi | Conselheiro | 26 de Maio de 2022 A | 93.989 | 0 | 0 | $0 |
| Charles Cohen | Conselheiro | 6 de Julho de 2021 M | 261.375 | 0 | 0 | $0 |
| George A Scangos | Conselheiro | 18 de Maio de 2020 S | 714.717 | 0 | 0 | $0 |
| FORMELA JEAN FRANCOIS | Conselheiro | 7 de Setembro de 2005 S | 584.519 | 0 | 0 | $0 |
| Mary C Beckerle | — | 10 de Agosto de 2026 S | 16.079 | 0 | 4 | $-1.932.572 |
| Sue Gail Eckhardt | — | 1 de Junho de 2026 S | 16.079 | 0 | 2 | $-660.828 |
| Jack L Wyszomierski | — | 1 de Junho de 2026 S | 284.384 | 0 | 2 | $-4.580.661 |
| Tomas J. Heyman | — | 27 de Maio de 2026 A | 50.649 | 0 | 0 | $0 |
| Bob Oliver | — | 27 de Maio de 2026 A | 29.487 | 0 | 2 | $-1.325.340 |
| Julie Smith | — | 27 de Maio de 2026 A | 28.957 | 0 | 3 | $-4.687.346 |
| Maria C Freire | — | 27 de Maio de 2026 A | 109.186 | 0 | 1 | $-949.164 |
| Stelios Papadopoulos | — | 27 de Maio de 2026 A | 1.197.595 | 0 | 1 | $-4.355.000 |
| George Poste | — | 27 de Maio de 2026 A | 127.199 | 0 | 1 | $-2.742.600 |
| Dana Aftab | — | 26 de Maio de 2026 S | 594.741 | 0 | 4 | $-7.701.255 |
| Frank Mccormick | — | 6 de Dezembro de 2013 A | — | 0 | 0 | $0 |
| Scott J. Garland | — | 18 de Setembro de 2013 A | — | 0 | 0 | $0 |
| Jason S Fisherman | — | 8 de Setembro de 2005 S | 7.881 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 4 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Farallon Capital Management, L.L.C., Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Roberts, Jr., Thomas G., Saito Edric C., Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. | 14 de Agosto de 2026 | 5,60% | Emenda | — | SEC |
| Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Fried, Richard B, Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Patel, Rajiv A., Roberts, Jr., Thomas G., Saito Edric C., Seybold, William, Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. ×8 declarações | 5 de Janeiro de 2026 | 5,90% | Emenda | — | SEC |
| Caligan Partners LP, David Johnson ×3 declarações | 2 de Junho de 2023 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 29 de Novembro de 2001 | — | Declaração inicial | M&A / venda | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 152 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| IDNA · iShares Trust | 3,47% | 131.275 SH | 8 de Agosto de 2026 | Diário |
| SAWG · ETF Series Solutions | 2,82% | 1.599 NS | 30 de Abril de 2026 | N-PORT |
| CANC · Tema ETF Trust | 2,78% | 96.885 NS | 31 de Maio de 2026 | N-PORT |
| XMHQ · Invesco Exchange-Traded Fund Trust | 2,67% | 2.774.135 SH | 8 de Agosto de 2026 | Diário |
| PBE · Invesco Exchange-Traded Fund Trust | 2,59% | 173.519 SH | 8 de Agosto de 2026 | Diário |
| MCOW · Pacer Funds Trust | 2,38% | 528 NS | 30 de Abril de 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 2,24% | 441.186 NS | 30 de Abril de 2026 | N-PORT |
| LYLD · Cambria ETF Trust | 2,01% | 2.722 NS | 30 de Abril de 2026 | N-PORT |
| AZTD · Tidal Trust I | 1,92% | 18.950 NS | 30 de Abril de 2026 | N-PORT |
| GRPM · Invesco Exchange-Traded Fund Trust | 1,84% | 172.947 SH | 8 de Agosto de 2026 | Diário |
| BBP · ETFis Series Trust I | 1,74% | 23.148 NS | 30 de Abril de 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 1,61% | 1.596 NS | 30 de Abril de 2026 | N-PORT |
| BUL · Pacer Funds Trust | 1,45% | 41.520 NS | 30 de Abril de 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,39% | 306.870 NS | 30 de Abril de 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1,36% | 5.563 NS | 30 de Abril de 2026 | N-PORT |
| RFG · Invesco Exchange-Traded Fund Trust | 1,30% | 86.397 SH | 8 de Agosto de 2026 | Diário |
| PTH · Invesco Exchange-Traded Fund Trust | 1,29% | 58.887 SH | 8 de Agosto de 2026 | Diário |
| COWG · Pacer Funds Trust | 1,26% | 616.432 NS | 30 de Abril de 2026 | N-PORT |
| TAX · EA Series Trust | 1,13% | 5.692 NS | 29 de Maio de 2026 | N-PORT |
| CALF · Pacer Funds Trust | 1,07% | 829.382 NS | 30 de Abril de 2026 | N-PORT |
| AFMC · First Trust Exchange-Traded Fund VI… | 1,03% | 32.938 NS | 31 de Maio de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 1,00% | 116.281 NS | 30 de Abril de 2026 | N-PORT |
| IBB · iShares Trust | 0,98% | 1.788.613 SH | 8 de Agosto de 2026 | Diário |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,93% | 13.681 SH | 8 de Agosto de 2026 | Diário |
| AGNG · Global X Funds | 0,92% | 14.988 NS | 31 de Maio de 2026 | N-PORT |
| OASC · Unified Series Trust | 0,91% | 15.171 NS | 31 de Maio de 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,90% | 25.550 NS | 30 de Abril de 2026 | N-PORT |
| FLOW · Global X Funds | 0,90% | 5.093 NS | 31 de Maio de 2026 | N-PORT |
| VAMO · Cambria ETF Trust | 0,88% | 16.470 NS | 30 de Abril de 2026 | N-PORT |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,72% | 248.016 SH | 8 de Agosto de 2026 | Diário |
| FLRG · FIDELITY COVINGTON TRUST | 0,72% | 45.672 NS | 30 de Abril de 2026 | N-PORT |
| IJK · iShares Trust | 0,70% | 1.469.020 SH | 8 de Agosto de 2026 | Diário |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,69% | 7.149 NS | 31 de Maio de 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,68% | 82.717 NS | 31 de Maio de 2026 | N-PORT |
| BIB · ProShares Trust | 0,66% | 9.600 NS | 31 de Maio de 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,64% | 4.091 NS | 31 de Maio de 2026 | N-PORT |
| VUSE · ETF Series Solutions | 0,63% | 85.930 NS | 31 de Maio de 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,60% | 2.080 NS | 30 de Abril de 2026 | N-PORT |
| PDP · Invesco Exchange-Traded Fund Trust | 0,59% | 165.207 SH | 8 de Agosto de 2026 | Diário |
| QGRO · AMERICAN CENTURY ETF TRUST | 0,58% | 255.026 NS | 31 de Maio de 2026 | N-PORT |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,53% | 19.762 NS | 31 de Maio de 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 0,51% | 502 NS | 30 de Abril de 2026 | N-PORT |
| VFQY · VANGUARD WELLINGTON FUND | 0,49% | 42.746 SH | 8 de Agosto de 2026 | Diário |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,48% | 64.828 NS | 30 de Abril de 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,47% | 5.095 NS | 30 de Abril de 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,45% | 147.282 SH | 8 de Agosto de 2026 | Diário |
| IQSM · New York Life Investments ETF Trust | 0,44% | 30.864 NS | 30 de Abril de 2026 | N-PORT |
| XJH · iShares Trust | 0,41% | 33.981 SH | 8 de Agosto de 2026 | Diário |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,41% | 47.960 NS | 30 de Abril de 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,41% | 33.169 SH | 8 de Agosto de 2026 | Diário |